



RECEIVED

JAN 24 2003

TECH CENTER 1600/2900

1644

PATENT

Case Docket No. CTLIMM.21CP1C

Date: December 3, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

~~7#5~~

Applicant : Simard et al.  
App. No. : 10/026,066  
Filed : December 7, 2001  
For : EPITOPE SYNCHRONIZATION  
IN ANTIGEN PRESENTING  
CELLS  
Examiner : Unassigned  
Group Art Unit : 1644

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on

December 3, 2002

(Date)

Marc T. Morley, Reg. No. 52,051

*M. T. Morley*

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) Information Disclosure Statement.
- (X) Form PTO-1449 listing one hundred and forty-eight (148) references, 13 copies of which are included herewith.
- (X) Return prepaid postcard.
- (X) The Commissioner is hereby authorized to charge any additional fees, which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.

*M. T. Morley*  
Marc T. Morley  
Registration No. 52,051  
Attorney of Record

CTLIMM.21CP1C



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
PATENT  
JAN 24 2003

TECH CENTER 1600/2900

Applicant : Simard et al. ) Group Art Unit: 1644  
)  
App. No. : 10/026,066 )  
)  
Filed : December 7, 2001 )  
)  
For : EPI TOPE )  
SYNCHRONIZATION IN )  
ANTIGEN PRESENTING )  
CELLS )  
)  
Examiner : Unassigned )

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing one hundred and forty-eight (148) references. One hundred thirty-five (135) of the references listed were of record in a prior application. The above-identified application is a continuation of U.S. Patent Application No. 10/005,905, filed November 7, 2001, which is a continuation-in-part of U.S. Patent Application Nos. 09/561,074, 09/560,465, 09/561,572 and 09/561,571 all filed April 28, 2000. Accordingly, pursuant to 37 C.F.R. § 1.98(d), these references are not enclosed. However, if copies of the references are necessary, they can be provided upon request.

Furthermore, pursuant to 37 C.F.R. § 1.98(a)(2), legible copies of thirteen (13) references that were not submitted in a prior application are enclosed herewith.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R.


**Appl. No.** : 10/026,066  
**Filed** : December 7, 2001

§ 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 12/3/02

By: 

Marc T. Morley  
Registration No. 52,051  
Attorney of Record  
2040 Main Street  
Fourteenth Floor  
Irvine, CA 92614  
(619) 235-8550

S:\DOCS\MTM\MTM-3113.DOC\083102

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
CTLIMM.21CP1CAPPLICATION NO.  
10/026,066INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Simard et al.FILING DATE  
December 7, 2001GROUP  
1644

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,439,199	03/27/84	Amkraut et al.			
	2.	4,937,190	06/26/90	Palmenberg et al.			
	3.	5,093,242	03/03/92	Bachmair et al.			
	4.	5,132,213	06/21/92	Bachmair et al.			
	5.	5,168,062	12/01/92	Stinski			
	6.	5,258,294	11/02/93	Boyle, et al.			
	7.	5,385,839	01/31/95	Stinski			
	8.	5,478,556	12/26/95	Elliot et al.			
	9.	5,496,721	03/05/96	Bachmair et al.			
	10.	5,580,859	12/03/96	Felgner et al.			
	11.	5,589,466	12/31/96	Felgner et al.			
	12.	5,646,017	07/08/97	Bachmair et al.			
	13.	5,679,647	10/21/97	Carson et al.			
	14.	5,698,396	12/16/97	Pfreundschuh			
	15.	5,733,548	03/31/98	Restifo et al.			
	16.	5,744,316	04/28/98	Lethe et al.			
	17.	5,747,269	05/05/98	Rammensee et al.			
	18.	5,844,075	12/01/98	Kawakami, et al.			
	19.	5,846,540	12/08/98	Restifo et al.			
	20.	5,847,097	12/08/98	Bachmair et al.			
	21.	5,856,187	01/05/99	Restifo et al.			
	22.	5,925,565	07/20/99	Berlioz et al.			
	23.	5,962,428	10/05/99	Carrano et al.			
	24.	5,989,565	11/23/99	Storkus et al.			
	25.	5,993,828	11/30/99	Morton			
	26.	5,994,523	11/30/99	Kawakami et al.			
	27.	6,008,200	12/28/99	Krieg			

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.21CP1C	APPLICATION NO. 10/026,066
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard et al.	
		FILING DATE December 7, 2001	GROUP 1644

RECEIVED

JAN 24 2003

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	28.	6,037,135	03/14/00	Kubo et al.		
	29.	6,060,273	05/09/00	Dirks et al.		
	30.	6,287,569	09/11/01	Kipps, et al.		

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	31.	74899	08/13/97	Ireland			
	32.	2,147,863	05/26/94	Canada			
	33.	DE 44 23 392 A1	01/11/96	Germany			
	34.	WO 92/01072	12/30/92	PCT			
	35.	EP 1 118 860 A1	07/25/01	EPO			
	36.	WO 92/21033	11/26/92	PCT			
	37.	EP 93/03175	04/06/95	PCT			
	38.	WO 96/01429	01/18/96	PCT			
	39.	WO 96/40209	12/19/96	PCT			
	40.	WO 97/34613	09/25/97	PCT			
	41.	WO 97/41440	11/06/97	PCT			
	42.	WO 98/13489	04/02/98	PCT			
	43.	WO 98/14464	04/09/98	PCT			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	44.	Aki et al., "Interferon- $\gamma$ Induces Different Subunit Organizations and Functional Diversity of Proteasomes," <i>J. Biochem.</i> , 115: 257-269 (1994)
	45.	Altuvia et al., "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets," <i>Human Immunology</i> , 58: 1-11 (1997)
	46.	Arnold et al., "Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules," <i>Nature</i> , 360: 171-174 (1992)
	47.	Ayyoub, et al., "Lack of tumor recognition by hTERT peptide 540-548-specific CD8 <sup>+</sup> T cells from melanoma patients reveals inefficient antigen processing," <i>Eur. J. Immunol.</i> , 31:2642-2651 (2001)
	48.	Bachman et al., "In vitro vs. in vivo assays for the assessment of T-and B cell function," <i>Curr. Opin. Immunol.</i> , 6: 320-326 (1994)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. CTLIMM.21CP1C	APPLICATION NO. 10/026,066 <b>RECEIVED</b>
	APPLICANT Simard et al.	DEC 10 2002
	FILING DATE December 7, 2001	GROUP 1644 <b>TECH CENTER 1600/2900</b>

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	49. Bettinotti et al., "Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy," <i>J. Immunol.</i> , 161: 877-889 (1998)
	50. Boes et al., "Interferon $\gamma$ Stimulation Modulates the Proteolytic Activity and Cleavage Site Preference of 20S Mouse Proteasomes," <i>J. Exp. Med.</i> , 179: 901-909 (1994)
	51. Brown et al., "Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes," <i>Nature</i> , 353: 355-357 (1991)
	52. Butterfield et al., "Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus," <i>J. Immunol.</i> , 161: 5607-5613 (1998)
	53. Chattergoon, et al., "Genetic Immunization: a new era in vaccines and immune therapeutics," <i>FASEB J.</i> , 11:753-763 (1997)
	54. Chaux et al., "Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced with MAGE-A1," <i>The Journal of Immunology</i> , 163: 2928-2936 (1999)
	55. Davis, H. L., "Plasmid DNA expression systems for the purpose of immunization," <i>Current Opinion in Immunology</i> , 8: 635-640 (1997)
	56. Dean et al., "Sequence requirements for plasmid nuclear import," <i>Experimental Cell Research</i> , 253: 713-722 (1999)
	57. DeGroot et al., "An Interactive Web Site Providing Major Histocompatibility Ligand Predictions: Application to HIV Research," <i>Aids Res. and Human Retrov.</i> , 13: 529-531 (1997)
	58. Dick et al., "Coordinated Dual Cleavages Induced by the Proteasome Regulator PA28 Lead to Dominant MHC Ligands," <i>Cell</i> , 86: 253-262 (1996)
	59. Dick, et al., "Proteolytic Processing of Ovalbumin and $\beta$ -galactosidase by the Proteasome to Yield Antigenic Peptides," <i>J. of Immunology</i> , 152:3884-3894 (1994)
	60. Driscoll et al., "MHC-linked LMP gene products specifically alter peptidase activities of the proteasome," <i>Nature</i> , 365: 262-264 (1993)
	61. Durrant, L.G., "Cancer vaccines," <i>Anti-cancer drugs</i> , 8: 727-733 (1997)
	62. Farrar et al., "The molecular cell biology of interferon- $\gamma$ and its receptor," <i>Annu. Rev. Immunol.</i> , 11: 571-611 (1993)
	63. Fiette et al., "Theiler's virus infection of 129Sv mice that lack the interferon $\alpha/\beta$ or interferon $\gamma$ receptors," <i>J. Exp. Med.</i> , 181: 2069-2076 (1995)
	64. Gaczynska et al., " $\gamma$ -Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes," <i>Nature</i> , 365: 264-267 (1993)
	65. Gale et al., "Evidence that hepatitis C Virus resistance to interferon is mediated through repression of the PKR protein kinase by the oncostructural 5A protein," <i>Virology</i> , 230: 217-227 (1997)
	66. Gileadi et al., "Generation of an Immunodominant CTL Epitope is Affected by Proteasome Subunit Composition and Stability of the Antigenic Protein," <i>Am. Assoc. of Immunol.</i> , 163: 6045-6052 (1999)
	67. Glynne et al., "A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC," <i>Nature</i> , 353: 357-360 (1991)
	68. Groettrup et al., "A role for the proteasome regulator PA28a in antigen presentation," <i>Nature</i> , 381: 166-168 (1996)
	69. Gulukota et al., "Two complementary methods for predicting peptides binding major histocompatibility complex molecules," <i>J. Mol. Biol.</i> , 267: 1258-1267 (1997)
	70. Gurunathan et al., "DNA vaccines: a key for inducing long-term cellular immunity," <i>Current Opinion in Immunology</i> , 12: 442-447 (2000)
	71. Heim et al., "Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway," <i>Journal of Virology</i> , 73: 8469-8475 (1999)
	72. Huang et al., "Immune response in mice that lack the interferon- $\gamma$ receptor," <i>Science</i> , 259: 1742-1745 (1993)
	73. International Search Report from co-pending Application No. PCT/US01/13806
	74. Jager et al., "Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo," <i>Int. J. Cancer</i> , 67: 54-62 (1996)
	75. Jager et al., "Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes," <i>J. Exp. Med.</i> , 187: 265-270 (1998)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. CTLIMM.21CP1C	APPLICATION NO. 10/026,066 <div style="text-align: right; font-size: 1.5em; font-weight: bold;">RECEIVED</div>
	APPLICANT Simard et al.	<div style="text-align: right; font-size: 1.2em;">DEC 10 2002</div>
	FILING DATE December 7, 2001	GROUP 1644 <b>TECH CENTER 1600/2900</b>

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	76. Kang et al., "Induction of Melanoma Reactive T Cells by Stimulator Cells Expressing Melanoma Epitope-Major Histocompatibility Complex Class I Fusion Proteins," <i>Cancer Res.</i> , 57: 202-205 (1997)
	77. Kawakami et al., "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>J. Immunother.</i> , 21:237-246 (1998)
	78. Kelly et al., "Second proteasome-related gene in the human MHC class II region," <i>Nature</i> , 353:667-668 (1991)
	79. Kittlesen et al., "Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development," <i>J. Immunol.</i> , 160: 2099-2106 (1998)
	80. Kundig et al., "Fibroblasts as efficient antigen-presenting cells in lymphoid organs," <i>Proc. Natl. Acad. Sci.</i> , 268:1343-1347 (1995)
	81. Kundig et al., "On the role of antigen in maintaining cytotoxic T cell memory," <i>Proc. Natl. Acad. Sci. USA</i> , 93:9716-9723 (1996)
	82. Larregina et al., "Direct Transfection and Activation of Human Cutaneous Dendritic Cells," <i>Gene Ther.</i> , 8:608-617 (2001)
	83. Lee et al., "Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients," <i>Nature Medicine</i> , 5:677-685 (1999)
	84. Leitner, et al., "DNA and RNA-based vaccines: principles, progress and prospects," <i>Vaccine</i> , 18:765-777 (2000)
	85. Levy et al., "Using ubiquitin to follow the metabolic fate of a protein," <i>Proc. Natl. Acad. Sci USA</i> , 93: 4907-4912 (1996)
	86. Linette et al., "In Vitro Priming with Adenovirus/gp100 Antigen-Transduced Dendritic Cells Reveals the Epitope Specificity of HLA-A*0201-Restricted CD8+ T Cells in Patients with Melanoma," <i>J. Immunol.</i> , 164: 3402-3412 (2000)
	87. Loftus et al., "Peptides Derived from Self-Proteins as Partial Agonists and Antagonists of Human CD8+ T-cell Clones Reactive to Melanoma/Melanocyte Epitope MART1(27-35)," <i>Cancer Res.</i> , 11: 2433-2439 (1998)
	88. Maksymowych et al., "Invasion by Salmonella typhimurium Induces Increased Expression of the LMP, MECL, and PA28 Proteasome Genes and Changes in the Peptide Repertoire of HLA-B27," <i>Infection and Immunity</i> , 66:4624-4632 (1998)
	89. Martinez et al., "Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene," <i>Nature</i> , 353:664-667 (1991)
	90. Mateo et al., "An HLA-A2 polypeptide vaccine for melanoma immunotherapy," <i>The Journal of Immunology</i> , 163: 4058-4063 (1999)
	91. McCluskie, et al., "Route and Method of Delivery of DNA Vaccine Influence Immune Response in Mice and Non-Human Primates," <i>Molecular Medicine</i> , 5:287-300 (1999)
	92. Meister et al., "Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences," <i>Vaccine</i> , 13: 581-591 (1995)
	93. Melief, C. J., <i>Cancerlit</i> , Database Accession No. 1998625858, "Towards T-cell immunotherapy of cancer," Meeting Abstract (1996)
	94. Miconnet et al., "Amino acid identity and/or position determine the proteasomal cleavage of the HLA-A *0201-restricted peptide tumor antigen MAGE-3," <i>The American Society for Biochemistry and Molecular Biology, Inc.</i> , page 20 (2000)
	95. Missale et al., "HLA-A31 and HLA-Aw68-restricted Cytotoxic T cell Responses to a Single Hepatitis B Virus Nucleocapsid Epitope during Acute Viral Hepatitis," <i>J. Exp. Med.</i> , 177: 751-762 (1993)
	96. Momburg et al., "Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation," <i>Nature</i> , 360: 174-177 (1992)
	97. Morel et al., "Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells," <i>Immunity</i> , 12: 107-117 (2000)
	98. Moskopidis et al., "Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus," <i>Journal of Virology</i> , 69: 7423-7429 (1995)
	99. Murphy et al., "Higher-Dose and Less Frequent Dendritic Cell Infusions with PSMA Peptides in Hormone-Refractory Metastatic Prostate Cancer Patients," <i>The Prostate</i> , 43: 59-62 (2000)
	100. Noppen et al., "Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2," <i>Int. J. Cancer</i> , 87: 241-246 (2000)
	101. Nussbaum et al., "Cleavage motifs of the yeast 20S proteasome $\beta$ subunits deduced from digest of enolase 1," <i>Proc. Natl. Acad. Sci USA</i> , 95: 12504-12509 (1998)

EXAMINER	DATE CONSIDERED
<b>*EXAMINER:</b> INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLIMM.21CP1C	APPLICATION NO. 10/026,066
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard et al.	DEC 10 2002
		FILING DATE December 7, 2001	GROUP 1644

RECEIVED

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	102. Oehen et al., "Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen," <i>J. Exp. Med.</i> 176: 1273-1281 (1992)
	103. Oldstone et al., "Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection," <i>Journal of Virology</i> , 69: 7423-7429 (1995)
	104. Ortiz-Navarrete et al., "Subunit of the '20S proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex," <i>Nature</i> , 353: 662-664 (1991)
	105. Pantaleo et al., "Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection," <i>Proc. Natl. Acad. Sci.</i> , 94: 9848-9853 (1997)
	106. Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains," <i>Journal of Immunology</i> , 152: 163 (1994)
	107. Perez-Diez et al., "Generation of CD8+ and CD4+ T-cell Response to Dendritic Cells Genetically Engineered to Express the MART-1/Melan-A Gene," <i>Cancer Res.</i> , 58: 5305-5309 (1998)
	108. Preckel et al., "Impaired Immunoproteasome Assembly and Immune Responses in PA28-I-Mice," <i>Science</i> , 286: 2162-2165 (1999)
	109. Puccetti et al., "Use of skin test assay to determine tumor-specific CD8+ T cell reactivity," <i>Eur. J. Immunol.</i> 24: 1446-1452 (1994)
	110. Rammensee et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> , 41: 178-228 (1995)
	111. Rammensee et al., "Peptide motifs: amino acids in peptide-MHC interactions," <i>Landes Bioscience Austin Texas</i> , Chapter 4: 217-369 (1997)
	112. Rammensee et al., "SYFPEITHI: Database for MHC ligands and peptide motifs," <i>Immunogenetics</i> , 50: 213-219 (1999)
	113. Raz et al., "Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization," <i>Proc. Natl. Acad. Sci. USA</i> , 93: 5141-5145 (1996)
	114. Reeves et al., "Retroviral Transduction of Human Dendritic Cells with a Tumor-Associated Antigen Gene," <i>Cancer Res.</i> , 56: 5672-5677 (1996)
	115. Rehmann et al., "The Cytotoxic T Lymphocyte Response to Multiple Hepatitis B Virus Polymerase Epitopes During and After Acute Viral Hepatitis," <i>Journal of Exp. Medicine</i> , 181: 1047-1058 (1995)
	116. Roberts et al., "Prediction of HIV Peptide Epitopes by a Novel Algorithm," <i>Aids Research and Human Retroviruses</i> , 12: 593-610 (1996)
	117. Rock et al., "Degradation of cell proteins and the generation of MHC class I-presented peptides," <i>Annu. Rev. Immunol.</i> , 17: 739-779 (1999)
	118. Roman et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants," <i>Nature Medicine</i> , 3: 849-854 (1997)
	119. Rosmorduc et al., "Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein," <i>Journal of General Virology</i> , 80: 1253-1262 (1999)
	120. Ryan et al., "A model for nonstoichiometric, cotranslational protein scission in eukaryotic ribosomes," <i>Bioorganic Chemistry</i> , 27: 55-79 (1999)
	121. Salmi et al., "Tumor endothelium selectively supports binding of IL-2 propagated tumor-infiltrating lymphocytes," <i>The Journal of Immunology</i> , 154: 6002-6012 (1995)
	122. Sato et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization," <i>Science</i> , 273: 352-354 (1996)
	123. Schirle et al., "Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens," <i>Journal of Immunological Methods</i> , 257: 1-16 (2001)
	124. Schneider, et al., "Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1," <i>Int. J. Cancer</i> , 75(3):451-458 (1998)
	125. Seipelt et al., "The structures of picomaviral proteinases," <i>Virus Research</i> , 62: 159-168 (1999)
	126. Sewell et al., "IFN-γ Exposes a Cryptic Cytotoxic T Lymphocyte Epitope in HIV-1 Reverse Transcriptase," <i>J. Immunol.</i> , 162: 7075-7079 (1999)
	127. Sijts et al., "Efficient Generation of a Hepatitis B Virus Cytotoxic T Lymphocyte Epitope Requires the Structural Features of Immunoproteasomes," <i>Journal of Exp. Medicine</i> , 191: 503-513 (2000)
	128. Speiser et al., "Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy," <i>Journal Exp. Medicine</i> , 186: 645-653 (1997)


EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. CTLMIM.21CP1C	APPLICATION NO. 10/028,066
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Simard et al.	DEC 10 2002
		FILING DATE December 7, 2001	GROUP 1644



RECEIVED

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	129. Stauss et al., "Induction of Cytotoxic T Lymphocytes with Peptides In Vitro: Identification of Candidate T-cell Epitopes in Human Papilloma," <i>Proc. Natl. Acad. Sci.</i> , 89: 7871-7875 (1992)
	130. Steinman et al., "The dendritic cell system and its role in immunogenicity," <i>Annual Review of Immunology</i> , 9: 271-296 (1991)
	131. Stumliolo et al., "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices," <i>Nature Biotechnology</i> , 17: 555-561 (1999)
	132. Taylor et al., "Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein," <i>Science</i> , 285: 107-110 (1999)
	133. Thomson et al., "Minimal epitopes expressed in a recombinant polypeptide protein are processed and presented to CD8 <sup>+</sup> cytotoxic T cells: Implications for vaccine design," <i>Proc. Natl. Acad. Sci. USA</i> , 92: 5845-5849 (1995)
	134. Tjoa et al., "Evaluation of Phase I/II Clinical Trials in Prostate Cancer with Dendritic Cells and PSMA Peptides," <i>The Prostate</i> , 36: 39-44 (1998)
	135. Twu et al., "Transcription of the human beta interferon gene is inhibited by hepatitis B virus," <i>Journal of Virology</i> , 63: 3065-3071 (1989)
	136. Valmori et al., "Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue," <i>J. Immunol.</i> , 164: 1125-1131 (2000)
	137. Van den Eynde et al., "Differential Processing of Class-I-Restricted Epitopes by the Standard Proteasome and the Immunoproteasome," <i>Curr. Opinion in Immunol.</i> , 13: 147-153 (2001)
	138. Van Kaer et al., "Altered Peptidase and Viral-Specific T Cell Response in LMP2 Mutant Mice," <i>Immunity</i> 1: 533-541 (1994)
	139. Vitiello et al., "Comparison of Cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance," <i>Euro. Jr. Immunol.</i> , 27: 671-678 (1997)
	140. Wang et al., "Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma," <i>Clin. Cancer Res.</i> , 10: 2756-2765 (1999)
	141. Yang et al., "Proteasomes Are Regulated By Interferon $\gamma$ : Implications For Antigen Processing," <i>Proc. Natl. Acad. Sci.</i> , 89: 4928-4932 (1992)
	142. Yewedell, et al., "MHC-Encoded Proteasome Subunits LMP2 and LMP7 Are Not Required for Efficient Antigen Presentation," <i>J. Immunology</i> 1994, 152:1163-1170 (1994)
	143. Young et al., "Dendritic Cells As Adjuvants For Class I Major Histocompatibility Complex-Restricted Antitumor Immunity," <i>J. Exp. Med.</i> , 183: 7-11 (1996)
	144. Zajac et al., "Enhanced Generation of Cytotoxic T Lymphocytes Using Recombinant Vaccinia Virus Expressing Human Tumor-Associated Antigens and B7 Costimulatory Molecules," <i>Cancer Res.</i> , 58: 4567-4571 (1998)
	145. Zajac et al., "Generation of Tumorcidal Cytotoxic T Lymphocytes from Healthy Donors after In Vitro Stimulation with a Replication-Incompetent Vaccinia Virus Encoding MART-1/Melan-A 27-35 Epitope," <i>Int. J. Cancer</i> , 71: 491-496 (1997)
	146. Zhai et al., "Antigen-Specific Tumor Vaccines. Development and Characterization of Recombinant Adenoviruses Encoding MART1 or gp100 for Cancer Therapy," <i>J. Immunol.</i> , 156: 700-710 (1996)
	147. Zipkin, I., "Cancer vaccines," <i>Bio Century</i> , 6: A1-A6 (1998)
	148. NCBI Blast Accession Number NP_005502

S:\DOCS\MTM\MTM-3114.DOC\083102

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	